Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Akcea Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Mar 1, 2024
Management Tracks
Jenne returns to Ionis
Plus: Krishnan to succeed CEO Driscoll at OncoNano and an update from Alvotech
BioCentury | Aug 3, 2023
Deals
Novartis and Ionis aim for best in class with latest Lp(a) deal
As new entrants join Lp(a) competition, Novartis and Ionis are looking beyond the first-mover advantage of Phase III candidate pelacarsen
BioCentury | May 9, 2022
Finance
VCs back Aspen with $147.5M as neuron replacement therapy heads toward clinic
Tapping GV, Lyfe and Revelation as series B leaders, biotech sought deep-pocketed syndicate with long-term view to match series A backer
BioCentury | Apr 9, 2022
Finance
5AM refuels, with eye toward new set of opportunities
As Levy, Soteropoulos join team, veteran early-stage investor has $750M in new funds to deploy
BioCentury | Apr 6, 2022
Management Tracks
Sabatini out at MIT
Plus Avidity expands role of MacLean and updates from Exscientia, eFFECTOR, Sofinnova and more
BioCentury | Jan 31, 2022
Deals
After review of Phase IIb data, Pfizer hands back CV program to Ionis
The pharma sunk $325M into vupanorsen, but won’t get its ‘mega-blockbuster’ in cardiovascular indications
BioCentury | Sep 28, 2021
Management Tracks
Peng joins Denali as chief commercial officer
Plus: Twist, Vaxart, Insilico, Gilde, Panakes and more
BioCentury | Aug 18, 2021
Management Tracks
Smith named CEO at Remix
Plus: Jubilant, Sparrow, n-Lorem, OncXerna and more
BioCentury | Jun 11, 2021
Management Tracks
Slavitt steps down from Biden’s pandemic response team; plus Ocugen, Flexion, Syros, Monte Rosa and more
Andy Slavitt has stepped down as senior adviser to the Biden administration’s coronavirus pandemic response team; the special government employee position limits service time to 130 days.
BioCentury | May 26, 2021
Management Tracks
Kim joins Orum as CFO; plus Neogene, Praxis, Sangamo, C4 and more
South Korea-based protein degradation play Orum Therapeutics Inc. hired Jae Won Kim as CFO. Kim was director of the healthcare investment banking team at Citi. T cell therapy company
Items per page:
1 - 10 of 109